Publications by authors named "Anna Resch"

Claim this Profile
N
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Nadia Harbeck, Denise Wrobel, Matthias Zaiss, Jürgen Terhaag, Dagmar Guth, Anna Resch

Breast Care (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
Diana Lüftner, Hans Tesch, Marcus Schmidt, Andreas D Hartkopf, Sarah Streicher, Anna Resch

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ).
Martin Schostak, Patrick de Geeter, Thomas Decker, Anna Resch, Claudia Quiering

Urol Int· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis